Syndrome News and Research

RSS

The Lancet publishes new Seminar on MERS

Middle East respiratory syndrome (MERS) has recently returned to the headlines as new cases have been exported to Korea and China. Experts are concerned that MERS cases continued to be detected in Saudi Arabia throughout the past year, and there appears to be little reduction in the number of cases since its first discovery three years ago. As the month of Ramadan approaches, with 1 million pilgrims expected to arrive in Saudi Arabia in June and July 2015, MERS remains a threat to global health security.

3 Jun 2015

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it has entered into a termination agreement with AstraZeneca, such that all the rights to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product candidate, tenapanor, are returned to Ardelyx.

3 Jun 2015

Feinberg physiology professor named recipient of 2015 AES Seed Grant

Today the American Epilepsy Society announced Anis Contractor, Ph.D., Associate Professor of Physiology at Northwestern University, Feinberg School of Medicine, as the recipient of a 2015 AES Seed Grant. Dr. Contractor's proposed research seeks to address a fundamental question about cellular and circuit level excitability in the mouse model of Dravet Syndrome.

3 Jun 2015

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Women who suffer from fibromyalgia benefit from a treatment regimen in a hyperbaric oxygen chamber, according to researchers at Rice University and institutes in Israel.

3 Jun 2015

UC Santa Cruz-led study offers new insights into molecular mechanisms of biological clock

A new study led by UC Santa Cruz researchers has found that a protein associated with cancer cells is a powerful suppressor of the biological clock that drives the daily ("circadian") rhythms of cells throughout the body.

3 Jun 2015

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

Northeastern University researchers report two approaches to eradicate Lyme disease

Northeastern University researchers have found that the bacterium that causes Lyme disease forms dormant persister cells, which are known to evade antibiotics. This significant finding, they said, could help explain why it's so difficult to treat the infection in some patients.

2 Jun 2015

New study on vestibulo-ocular dysfunction in pediatric sports-related concussion

Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.

2 Jun 2015

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

2 Jun 2015

More patients experience phantom eye symptoms every day, say University of Liverpool researchers

Researchers from the University of Liverpool have found that approximately half of patients who have an eye removed because of a form of eye cancer experience 'phantom eye syndrome.'

2 Jun 2015

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma.

2 Jun 2015

Chronic exposure to bacteria may lead to development of Type 2 diabetes

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers (H. pylori bacteria).

2 Jun 2015

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.

2 Jun 2015

BioLight Life Sciences reports operational and financial results for Q1 2015

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the first quarter ended March 31, 2015.

1 Jun 2015

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the results of a study identifying the clinical benefit of targeted therapy in colorectal cancer (CRC) with high microsatellite instability (MSI-H), a predisposition that occurs in 15% of all CRCs causing significantly different prognosis and response to treatment.

1 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Syndrome News and Research

The Lancet publishes new Seminar on MERS

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Feinberg physiology professor named recipient of 2015 AES Seed Grant

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

UC Santa Cruz-led study offers new insights into molecular mechanisms of biological clock

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Northeastern University researchers report two approaches to eradicate Lyme disease

New study on vestibulo-ocular dysfunction in pediatric sports-related concussion

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

More patients experience phantom eye symptoms every day, say University of Liverpool researchers

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Chronic exposure to bacteria may lead to development of Type 2 diabetes

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

BioLight Life Sciences reports operational and financial results for Q1 2015

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Myriad Genetics to highlight new clinical studies on myRisk Hereditary Cancer test at ASCO 2015

Pulmonary rehabilitation ‘should include sleep assessment’

‘Real-world’ sunitinib findings support trial results

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News